JAKPot for treating bone loss
Researchers report that JAK inhibitors – a class of approved anti-inflammatory drugs – prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Review BioFIT 2019: A great first edition in Marseille
For its first phocean edition, BioFIT confirms its status as the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. Over 1,150 attendees from over 35 countries attended BioFIT’s 8th edition: 120+ exhibitors, 70 speakers, 16 conferences and 4 projects elected as the most innovative in their categories were gathered in Marseille at Parc Chanot on December 10th and 11th.
Mereo BioPharma raise money to back Phase III trials
Mereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.
Stilla raises €20m in series B financing round
French Stilla Technologies SA raised €20m in a Series B funding to boost digital PCR-based genetic testing.
BIH scientists optimise CRISPR gene scissors
Targeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Azafaros BV raises €25m in Series A round
Dutch biotech Azafaros B.V. has closed a €25m Series A financing round.
Researchers identify roots of childhood asthma
Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.
MaaT Pharma raise €18m to advance clinical pipeline
MaaT Pharma SA has announced €18m Series B financing to boost its microbiome biotherapeutics pipeline.
Valneva raises US$85m
French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
EMA greenlights 15 new meds
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.